deferoxamine has been researched along with Cardiovascular Diseases in 13 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiovascular diseases are a common cause of morbidity and mortality in subjects on regular hemodialysis." | 5.40 | Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. ( Alnahal, AA; Fathy, A; Fathy, T; Tahan, M, 2014) |
| "Deferoxamine treatment was initiated at 10 mg/kg per hour but, after the precipitous death of the first animal, was progressively reduced to 1." | 5.28 | Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease. ( Coalson, JJ; deLemos, JA; deLemos, RA; Gerstmann, DR; Null, DM; Roberts, RJ, 1990) |
| "We used combined therapy with desferrioxamine and deferiprone to treat 79 patients with severe iron overload (serum ferritin higher than 3000 ng/mL) who had low compliance with subcutaneous desferrioxamine." | 3.73 | Combined therapy with deferiprone and desferrioxamine in thalassemia major. ( Agus, A; Bina, P; Crobu, G; Defraia, E; Dessì, C; Galanello, R; Leoni, G; Muroni, PP; Origa, R, 2005) |
| "Cardiac iron overload was induced to a greater extent than in a previous study by feeding the mice with an iron-enriched diet for 4 months." | 1.43 | Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S, 2016) |
| "Cardiovascular diseases are a common cause of morbidity and mortality in subjects on regular hemodialysis." | 1.40 | Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. ( Alnahal, AA; Fathy, A; Fathy, T; Tahan, M, 2014) |
| "Deferoxamine treatment was initiated at 10 mg/kg per hour but, after the precipitous death of the first animal, was progressively reduced to 1." | 1.28 | Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease. ( Coalson, JJ; deLemos, JA; deLemos, RA; Gerstmann, DR; Null, DM; Roberts, RJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 1 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 2 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 1 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 1 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 1 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Chen, Y | 1 |
| Li, X | 1 |
| Wang, S | 1 |
| Miao, R | 1 |
| Zhong, J | 1 |
| Alnahal, AA | 1 |
| Tahan, M | 1 |
| Fathy, A | 1 |
| Fathy, T | 1 |
| Kumfu, S | 1 |
| Chattipakorn, SC | 1 |
| Fucharoen, S | 1 |
| Chattipakorn, N | 1 |
| Origa, R | 1 |
| Bina, P | 1 |
| Agus, A | 1 |
| Crobu, G | 1 |
| Defraia, E | 1 |
| Dessì, C | 1 |
| Leoni, G | 1 |
| Muroni, PP | 1 |
| Galanello, R | 1 |
| Atiq, M | 1 |
| Bana, M | 1 |
| Ahmed, US | 1 |
| Bano, S | 1 |
| Yousuf, M | 1 |
| Fadoo, Z | 1 |
| Khurshid, M | 1 |
| Henretig, FM | 2 |
| Temple, AR | 2 |
| Borgna-Pignatti, C | 1 |
| Zurlo, MG | 1 |
| DeStefano, P | 1 |
| Boffa, C | 1 |
| DeSanctis, V | 1 |
| DiPalma, A | 1 |
| DiGregorio, L | 1 |
| Melevendi, C | 1 |
| Piga, A | 1 |
| Sabato, V | 1 |
| Elihu, N | 1 |
| Anandasbapathy, S | 1 |
| Frishman, WH | 1 |
| Roodpeyma, S | 1 |
| Alebouye, M | 1 |
| Kamali, Z | 1 |
| Prati, D | 1 |
| deLemos, RA | 1 |
| Roberts, RJ | 1 |
| Coalson, JJ | 1 |
| deLemos, JA | 1 |
| Null, DM | 1 |
| Gerstmann, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Metoprolol Succinate on the Cardiac Function of Patients With Thalassemia Cardiomyopathy a Double Blind Randomized Study[NCT01863173] | Phase 2/Phase 3 | 45 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for deferoxamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Deferoxamine; Ferroptosis; Humans; Hypertension; Iron; Lipid Peroxidation; | 2023 |
Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane.
Topics: Antibiotics, Antineoplastic; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Deferoxam | 1998 |
Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major.
Topics: Anemia, Hemolytic; beta-Thalassemia; Blood Group Incompatibility; Blood Transfusion; Cardiovascular | 2000 |
9 other studies available for deferoxamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload.
Topics: Adult; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Carotid Intima-Media Thic | 2014 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Ca | 2016 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: Adolescent; Adult; Agranulocytosis; beta-Thalassemia; Cardiovascular Diseases; Child; Deferiprone; D | 2005 |
Cardiac disease in beta-thalassaemia major: Is it reversible?
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cardiotonic Agents; Cardiovascular Diseases; | 2006 |
Acute iron poisoning in children.
Topics: Cardiovascular Diseases; Cathartics; Central Nervous System Diseases; Chemical and Drug Induced Live | 1984 |
Acute iron poisoning in children.
Topics: Acute Disease; Animals; Cardiovascular Diseases; Central Nervous System Diseases; Child; Child, Pres | 1984 |
Outcome of thalassemia treated with conventional therapy.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Cardiovascular Diseases; Cause of Death; Chelation | 1993 |
Chelation therapy and cardiac status in young patients with thalassemia major.
Topics: Adolescent; beta-Thalassemia; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Child; C | 2000 |
Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease.
Topics: Animals; Cardiovascular Diseases; Deferoxamine; Drug Evaluation, Preclinical; Female; Humans; Hyalin | 1990 |